보도자료
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Copyright 2020 - BIXINK | Terms of Use | Contact
서울특별시 강남구 논현로 561 6층 [06125]
6F, 561 Nonhyeon-ro, Gangnam-gu, Seoul 06125, Republic of Korea
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea